Tag: Kodiak Sciences

October 7, 2019 Off

Kodiak’s ophthalmology treatment phase 1 study has satisfactory results

By Dino Mustafić

Kodiak Sciences will present emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-related macular degeneration (wet AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) in San Francisco, in an upcoming event, at the Annual Meeting of the American Academy of Ophthalmology (AAO).